Literature DB >> 31743241

Novel options for failing allograft in kidney transplanted patients to avoid or defer dialysis therapy.

Ekamol Tantisattamo1, Ramy M Hanna, Uttam G Reddy, Hirohito Ichii, Donald C Dafoe, Gabriel M Danovitch, Kamyar Kalantar-Zadeh.   

Abstract

PURPOSE OF REVIEW: Despite improvement in short-term renal allograft survival in recent years, renal transplant recipients (RTR) have poorer long-term allograft outcomes. Allograft function slowly declines with periods of stable function similar to natural progression of chronic kidney disease in nontransplant population. Nearly all RTR transitions to failing renal allograft (FRG) period and require transition to dialysis. Conservative chronic kidney disease management before transition to end-stage renal disease is an increasingly important topic; however, there is limited data in RTR regarding how to delay dialysis initiation with conservative management. RECENT
FINDINGS: Since immunological and nonimmunological factors unique to RTR contribute to decline in allograft function, therapies to slow progression of FRG should take both sets of factors into account. Renal replacement therapy either incremental dialysis or rekidney transplantation should be explored. This required taking benefits and risks of continuing immunosuppressive medications into account when allograft nephrectomy may be necessary.
SUMMARY: FRG may benefit from various interventions to slow progression of worsening allograft function. Until there are stronger evidence to guide interventions to preserve renal function, extrapolating evidence from nontransplant patients and clinical judgment are necessary. The goal is to provide individualized care for conservative management of RTR with FRG.

Entities:  

Mesh:

Year:  2020        PMID: 31743241      PMCID: PMC7454043          DOI: 10.1097/MNH.0000000000000572

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   3.416


  97 in total

1.  Correction of postkidney transplant anemia reduces progression of allograft nephropathy.

Authors:  Gabriel Choukroun; Nassim Kamar; Bertrand Dussol; Isabelle Etienne; Elisabeth Cassuto-Viguier; Olivier Toupance; François Glowacki; Bruno Moulin; Yvon Lebranchu; Guy Touchard; Maïté Jaureguy; Nicolas Pallet; Yannick Le Meur; Lionel Rostaing; Frank Martinez
Journal:  J Am Soc Nephrol       Date:  2011-12-22       Impact factor: 10.121

2.  Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients.

Authors:  E Lars Penne; Neelke C van der Weerd; Muriel P C Grooteman; Albert H A Mazairac; Marinus A van den Dorpel; Menso J Nubé; Michiel L Bots; Renée Lévesque; Piet M ter Wee; Peter J Blankestijn
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 8.237

3.  The clinical significance of medial arterial calcification in end-stage renal disease in women.

Authors:  Nada Abou-Hassan; Ekamol Tantisattamo; Ellen T D'Orsi; W Charles O'Neill
Journal:  Kidney Int       Date:  2014-05-28       Impact factor: 10.612

4.  Returning to haemodialysis after kidney allograft failure: a survival study with propensity score matching.

Authors:  Javier Varas; María José Pérez-Sáez; Rosa Ramos; Jose Ignacio Merello; Angel Luis M de Francisco; José Luño; Manuel Praga; Pedro Aljama; Julio Pascual
Journal:  Nephrol Dial Transplant       Date:  2019-04-01       Impact factor: 5.992

5.  Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.

Authors:  Tariq Shafi; Bernard G Jaar; Laura C Plantinga; Nancy E Fink; John H Sadler; Rulan S Parekh; Neil R Powe; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2010-06-03       Impact factor: 8.860

Review 6.  Dietary protein intake and chronic kidney disease.

Authors:  Gang Jee Ko; Yoshitsugu Obi; Amanda R Tortorici; Kamyar Kalantar-Zadeh
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2017-01       Impact factor: 4.294

7.  Renal retransplants: effect of primary allograft nephrectomy on early function, acute rejection and outcome.

Authors:  V Douzdjian; J C Rice; R W Carson; K K Gugliuzza; J C Fish
Journal:  Clin Transplant       Date:  1996-04       Impact factor: 2.863

8.  The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD )-2.

Authors:  Fabian Termorshuizen; Johanna C Korevaar; Friedo W Dekker; Jeannette G van Manen; Elisabeth W Boeschoten; Raymond T Krediet
Journal:  Am J Kidney Dis       Date:  2003-06       Impact factor: 8.860

9.  The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy.

Authors:  Jeffrey S Zaltzman; Michelle Nash; Rick Chiu; Ramesh Prasad
Journal:  Nephrol Dial Transplant       Date:  2004-04       Impact factor: 5.992

10.  The incremental treatment of ESRD: a low-protein diet combined with weekly hemodialysis may be beneficial for selected patients.

Authors:  Stefania Caria; Adamasco Cupisti; Giovanna Sau; Piergiorgio Bolasco
Journal:  BMC Nephrol       Date:  2014-10-29       Impact factor: 2.388

View more
  2 in total

Review 1.  Plant-Dominant Low-Protein Diet for Conservative Management of Chronic Kidney Disease.

Authors:  Kamyar Kalantar-Zadeh; Shivam Joshi; Rebecca Schlueter; Joanne Cooke; Amanda Brown-Tortorici; Meghan Donnelly; Sherry Schulman; Wei-Ling Lau; Connie M Rhee; Elani Streja; Ekamol Tantisattamo; Antoney J Ferrey; Ramy Hanna; Joline L T Chen; Shaista Malik; Danh V Nguyen; Susan T Crowley; Csaba P Kovesdy
Journal:  Nutrients       Date:  2020-06-29       Impact factor: 5.717

2.  Comparison of outcomes of peritoneal dialysis between patients after failed kidney transplant and transplant-naïve patients: a meta-analysis of observational studies.

Authors:  Xiaohua Meng; Weifei Wu; Shuang Xu; Zhiqun Cheng
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.